WCTD2016 Abstract Topics Cardiovascular Outcome Studies (12 abstracts)
Years of Life Gained by Multifactorial Intervention in Patients with Type 2 Diabetes and Microalbuminuria – 21 Years Follow-Up on the Steno-2 Study
Jens Ollgaard 1, , Peter Gæde 1, , Bendix Carstensen 4 , Peter Rossing 2, , Henrik Lund-Andersen 6, , Hans-Henrik Parving 6, & Oluf Pedersen 9
1Cardiology and Endocrinology, Slagelse Hospital, Denmark; 2Complications Research, Steno Diabetes Center, Denmark; 3Institute for Regional Health Research, University of Southern Denmark, Denmark; 4Epidemiology, Steno Diabetes Center, Denmark; 5Epidemiology, Aarhus University, Denmark; 6Epidemiology, University of Copenhagen, Denmark; 7Eye Clinic, Cepital Region, Denmark; 8Department of Medical Endocrinology, Cepital Region Hospital, Denmark; 9Section of Metabolic Genetics, Novo Nordisk Foundation Center for Basic Metabolic Research, Denmark.
Aims: To study the potential long-term impact of a 7.8 years intensified, multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria in terms of gained years of life and years free from incident cardiovascular disease.
Methods: The original intervention (mean treatment duration 7.8 years) involved 160 patients with type 2 diabetes and microalbuminuria that were randomly assigned to either conventional therapy or intensified, multifactorial treatment including both behavioral and pharmacological approaches. After 7.8 years the study continued as an observational follow-up with all patients receiving treatment as for the original intensive-therapy group. The primary end-point of this follow-up 21.2 years after intervention start was difference in median survival time between the original treatment groups with and without incident cardiovascular disease.
Results: 38 intensive-therapy patients vs 55 conventional-therapy patients died during follow-up (hazard ratio 0.55 [0.36, 0.83, P=0.005]. The patients in the intensive-therapy group survived for a median of 7.9 years longer than the conventional-therapy group patients. Median time before first cardiovascular event after randomization was 8.1 years longer in the intensive-therapy group (P=0.001).
The hazard for all microvascular complications was decreased in the intensive-therapy group (hazard ratios 0.52–0.67), except for peripheral neuropathy (hazard ratio 1.12).
Conclusions: At 21.2 years of follow up of 7.8 years of intensified, multifactorial, target driven treatment of type 2 diabetes with microalbuminuria, we demonstrate a median of 7.9 years of gain of life. The increase in life span is matched by the time free from incident cardiovascular disease.
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more